We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Kidney Transplant Rejection Linked to New Mismatch Locus

By LabMedica International staff writers
Posted on 13 Jun 2019
Print article
Image: The NimbleGen MS 200 CGH LOH microarray detection scanner (Photo courtesy of Roche).
Image: The NimbleGen MS 200 CGH LOH microarray detection scanner (Photo courtesy of Roche).
Approximately 20% of the kidney waiting list in the USA consists of candidates whose allografts have failed. Acute rejection is one of the strongest predictors of decreased allograft survival.

In the context of kidney transplantation, genomic incompatibilities between donor and recipient may lead to allosensitization against new antigens. A new form of genetic mismatch, or “genomic collision”, has been identified between kidney transplant recipients and organ donors that appears to increase the risk of allograft rejection.

A large team of scientists led by those at Columbia University (New York, NY, USA) performed a two-stage genetic association study of kidney allograft rejection. The study aimed at uncovering high-priority copy number variants influencing kidney allograft rejection in more than 700 transplant recipients. In particular, they focused on the so-called genomic collision situations, in which transplant recipients carried two copies of a deletion that was not homozygous in the organ donor.

The identification of alloantibodies was performed with the use of protein arrays, enzyme-linked immunosorbent assays (ELISAs), and Western blot analyses. The team used the NimbleGen array-based comparative genome hybridization to search for 50 suspicious deletions affecting protein-coding parts of the genome in 705 kidney transplant recipients. From there, they searched for associations with kidney allograft rejection in a “time-to-event survival analysis” in the patients, who were followed for more than eight-and-a-half years, on average.

In the discovery cohort, which included 705 recipients, they found a significant association with allograft rejection at the LIMS1 locus represented by rs893403 (hazard ratio with the risk genotype versus the non-risk genotypes, 1.84). This effect was replicated under the genomic-collision model in three independent cohorts involving a total of 2,004 donor–recipient pairs (hazard ratio, 1.55). In the combined analysis (discovery cohort plus replication cohorts), the risk genotype was associated with a higher risk of rejection than the non-risk genotype (hazard ratio, 1.63). The team identified a specific antibody response against LIMS1, a kidney-expressed protein encoded within the collision locus. The response involved predominantly IgG2 and IgG3 antibody subclasses.

The team got further evidence for the hypothesis following a functional analysis of the rejection-related risk variant, and sero-reactivity experiments that relied on protein array data for hundreds more kidney transplant recipients who did or did not experience allograft rejection. The authors noted that the LIMS1 protein also appears to be expressed in other commonly transplanted organs, including the heart and lung, though they cautioned that follow-up studies will be useful in determining whether our findings are generalizable to other organs. The study was published on May 16, 2019, in The New England Journal of Medicine.

Related Links:
Columbia University

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test
New
Amoebiasis Test
ELI.H.A Amoeba

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.